<DOC>
	<DOCNO>NCT02445131</DOCNO>
	<brief_summary>The CLL2-BCG-trial prospective , open-label , multicenter phase-II-trial evaluate efficacy safety sequential regimen debulking bendamustine follow induction GA101 ( obinutuzumab ) CAL-101 ( idelalisib ) follow CAL-101 GA101-maintenance CLL patient</brief_summary>
	<brief_title>Sequential Regimen Bendamustine-Debulking Followed CAL-101 GA101-Induction -Maintenance CLL ( CLL2-BCG )</brief_title>
	<detailed_description>In CLL2-BCG-trial , total 62 patient allcomer CLL population ( irrespective physical fitness , previous therapy prognostic factor ) indication treatment include . Patients receive 2 cycle debulking treatment bendamustine unless contraindication ( e.g . refractoriness ) present debulking indicate due low tumor burden . Afterwards , 6 cycle induction treatment GA101 ( obinutuzumab , 3 dos first cycle monthly cycle 2-6 ) CAL-101 ( idelalisib , continuously start cycle 2 ) apply . The primary endpoint overall response rate assess final restaging ( 2 month end induction treatment ) . Patients benefit treatment receive therapy GA101 ( 3 monthly ) CAL-101 ( continuously ) maintenance phase 24 month . Maintenance treatment stop case achievement complete remission confirmation MRD ( minimal residual disease ) negativity peripheral blood unacceptable toxicity progression occur .</detailed_description>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>document chronic lymphocytic leukemia ( CLL ) require treatment accord International Working Group CLL ( iwCLL ) criterion adequate hematologic function : platelet ≥ 25.000/µl , neutrophil ≥ 1.000/µl hemoglobin ≥8.0 g/dL , unless directly attributable patient´s CLL ( e.g . bone marrow infiltration ) adequate renal function : creatinine clearance ≥30ml/min calculate accord modify formula Cockcroft Gault directly measure 24 hr . urine collection adequate liver function : total bilirubin ≤1,5x , aspartate aminotransferase ( AST ) / alanin aminotransferase ( ALT ) ≤2.5x institutional upper limit normal ( ULN ) value , unless directly attributable patient 's CLL Gilbert 's Syndrome negative serological test hepatitis B , negative test hepatitisC RNA negative HIV test within 6 week prior registration age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 , ECOG 3 permit related CLL life expectancy ≥ 6 month ability willingness provide write informed consent adhere study visit schedule protocol requirement transformation CLL ( i.e . Richter 's transformation , prolymphocytic leukemia ) know central nervous system ( CNS ) involvement confirm progressive multifocal leukoencephalopathy ( PML ) malignancy CLL currently require systemic therapy uncontrolled infection require systemic treatment comorbidity organ system impairment rat cumulative illness rating scale ( CIRS ) score 4 , exclude eyes/ears/nose/throat/larynx organ system lifethreatening illness , medical condition organ system dysfunction investigator´s opinion could compromise patient safety interfere absorption metabolism study drug ( e.g , inability swallow tablet impaired resorption gastrointestinal tract ) ongoing inflammatory bowel disease ongoing drug induce pneumonitis use investigational agent would interfere study drug ≤28 day prior registration know hypersensitivity GA101 ( obinutuzumab ) , CAL101 ( idelalisib ) excipients pregnant woman nurse mother fertile men woman childbearing potential unless surgically sterile ≥ 2 year onset menopause , willing use two method reliable contraception include one highly effective ( Pearl Index &lt; 1 ) one additional effective ( barrier ) method study treatment 18 month end study treatment vaccination live vaccine ≤28 day prior registration legal incapacity prisoner subject institutionalized regulatory court order person dependence sponsor investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CLL</keyword>
</DOC>